{"entity":{"id":"arid2","kind":"target","name":"ARID2","aka":["AT-rich interaction domain 2","AT-rich interactive domain-containing protein 2","KIAA1557","DKFZp686G052","FLJ30619","BAF200","SMARCF3","ZIPZAP","p200"],"tldr":"ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.","summary":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.98). IntOGen calls it a driver in 36 cohorts (3 activating, 33 loss-of-function), covering Cholangiocarcinoma, Cutaneous Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Glioblastoma, Gallbladder Cancer and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18037","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18037"},{"label":"UniProt Q68CP9","url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry"},{"label":"NCBI Gene 196528","url":"https://www.ncbi.nlm.nih.gov/gene/196528"},{"label":"Ensembl ENSG00000189079","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000189079"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["skin-cancer","hcc","esophageal","gastric","biliary-tract-cancer","head-and-neck","nasopharyngeal","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 33 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ARID2","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:18037","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18037","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q68CP9","url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ARID2","url":"https://civicdb.org/features/19838","note":"1 evidence items, 0 assertions, 2 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000189079","url":"https://platform.opentargets.org/target/ENSG00000189079/associations","note":"association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.53, oesophageal cancer 0.57, hepatocellular carcinoma 0.63, melanoma 0.72, skin cancer 0.67, lung cancer 0.51 (GraphQL API, CC0)"},{"label":"IntOGen ARID2","url":"https://www.intogen.org/search?gene=ARID2","note":"driver in 36 cohorts (Act 3, LoF 33); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"many-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ARID2: RNA low tissue specificity; no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Hepatocellular carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Biliary tract cancer (all types), Head and neck squamous cell carcinoma, Nasopharyngeal carcinoma and more); Open Targets associates it with 2 specific cancer types at or above 0.5 (hepatocellular carcinoma, melanoma). (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q68CP9","url":"https://www.uniprot.org/uniprotkb/Q68CP9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ARID2","url":"https://civicdb.org/features/19838","note":"1 evidence items, 0 assertions, 2 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)"},{"label":"IntOGen ARID2","url":"https://www.intogen.org/search?gene=ARID2","note":"driver in 36 cohorts (Act 3, LoF 33); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas ARID2 tissue","url":"https://www.proteinatlas.org/ENSG00000189079-ARID2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000189079 associations","url":"https://platform.opentargets.org/target/ENSG00000189079/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:18037","ensembl":"ENSG00000189079","uniprot":"Q68CP9","entrez":"196528","firstDescribed":2000,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2000, \"Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/10997877/","biology":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes. Location: Nucleus (UniProt). Locus 12q12 (HGNC).","whereFound":["Skin cancer: Open Targets association 0.67 with skin cancer (MONDO_0002898)","Hepatocellular carcinoma: Open Targets association 0.63 with hepatocellular carcinoma (MONDO_0007256); CIViC evidence names this disease","Oesophageal cancer: Open Targets association 0.57 with oesophageal cancer (MONDO_0007576); IntOGen driver in 3 cohorts (ESCA, ESCC)","Gastric & gastro-oesophageal junction cancer: IntOGen driver in 2 cohorts (STAD)","Biliary tract cancer: Open Targets association 0.57 with biliary tract cancer (MONDO_0003060)","Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/arid2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"paper":[{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/"}]}}